NexImmune, Inc. (NEXI)

NASDAQ: NEXI · IEX Real-Time Price · USD
0.210
+0.008 (4.07%)
At close: Sep 27, 2023, 4:00 PM
0.200
-0.010 (-4.76%)
After-hours: Sep 27, 2023, 4:03 PM EDT
4.07%
Market Cap 5.47M
Revenue (ttm) n/a
Net Income (ttm) -48.75M
Shares Out 26.08M
EPS (ttm) -1.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 165,114
Open 0.210
Previous Close 0.202
Day's Range 0.195 - 0.214
52-Week Range 0.190 - 0.814
Beta 2.21
Analysts Hold
Price Target n/a
Earnings Date Nov 13, 2023

About NEXI

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 50
Stock Exchange NASDAQ
Ticker Symbol NEXI
Full Company Profile

Financial Performance

Financial Statements

News

NexImmune Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy

GAITHERSBURG, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directin...

27 days ago - GlobeNewsWire

NexImmune Reports Second Quarter 2023 Financial Results and Provides Business Updates

GAITHERSBURG, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune resp...

6 weeks ago - GlobeNewsWire

NexImmune Presents Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-HSCT AML at the American Society of Clinical Oncology 2023 Annual Meeting

- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001 is well tolerated with a favorable safety profile, including no grade > 3 tre...

4 months ago - GlobeNewsWire

NexImmune Announces Poster Presentation at the 2023 FOCIS Annual Meeting

AIM nanoparticle approach can identify select EBV-specific T cell defects in patients with multiple sclerosis and may enable killing of EBV+ cells believed to be a contributing factor in this disease

4 months ago - GlobeNewsWire

NexImmune Reports First Quarter 2023 Financial Results and Provides Business Updates

GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune respo...

4 months ago - GlobeNewsWire

NexImmune Announces Presentation of Phase 1/2 Clinical Data at the 2023 American Society of Clinical Oncology Annual Meeting

GAITHERSBURG, Md., April 26, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune res...

5 months ago - GlobeNewsWire

NexImmune Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

GAITHERSBURG, Md., March 28, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune res...

6 months ago - GlobeNewsWire

NexImmune Announces Data Showing AIM ACT T cells Enhance the Response to Bispecific T cell Engager Therapy at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

GAITHERSBURG, Md., Feb. 16, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune resp...

7 months ago - GlobeNewsWire

NexImmune Announces Publication in Frontiers in Medicine Highlighting the Company's AIM Platform to Treat Viral Diseases

GAITHERSBURG, Md., Jan. 18, 2023 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune resp...

9 months ago - GlobeNewsWire

NexImmune Reports Third Quarter 2022 Financial Results and Announces Strategic Update

GAITHERSBURG, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune resp...

11 months ago - GlobeNewsWire

NexImmune Announces Research Collaboration with National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH)

The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunological diseases The collaboration will explore EBV and HTLV-1 antigen-specific immune responses in immunologic...

1 year ago - GlobeNewsWire

NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targ...

1 year ago - GlobeNewsWire

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

GENEVA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing unique approaches to T cell i...

1 year ago - Business Wire

NexImmune Reports Second Quarter 2022 Financial Results and Highlights FDA Clearance of IND for NEXI-003 for the Treatment of HPV-Related Cancers

GAITHERSBURG, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targe...

1 year ago - GlobeNewsWire

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

GAITHERSBURG, Md., July 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targe...

1 year ago - GlobeNewsWire

NexImmune Reports First Quarter 2022 Financial Results and Provides Business Updates

GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

1 year ago - GlobeNewsWire

NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), Yale and JDRF have begun a two-year project to explore the use of NexImmune's AIM nanoparticles in combination with ...

1 year ago - GlobeNewsWire

NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors

GAITHERSBURG, Md., May 10, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a target...

1 year ago - GlobeNewsWire

NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center

GAITHERSBURG, Md., April 26, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targ...

1 year ago - GlobeNewsWire

NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer

Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in the field of artificial antigen presenting cell (aAPC) technology Dr. Oelke is a scientific co-founder of NexImmune and a pioneer in ...

1 year ago - GlobeNewsWire

Executives Buy More Than $1M Of 5 Penny Stocks

The Dow Jones jumped around 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: PFMTRIBTTNXP
1 year ago - Benzinga

Insiders Buying These 5 Penny Stocks

The Dow Jones surged around 350 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: LVONNRCATSSKN
1 year ago - Benzinga

NexImmune, Zephyr Join Forces For Oncology Target Discovery, Validation

NexImmune Inc (NASDAQ: NEXI) and Zephyr AI have announced a strategic partnership focusing on discovering and validating novel targets for new T-cell-mediated therapies in oncology.  The collaboration...

1 year ago - Benzinga

NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation

GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr) today announced a strategic partnership focusing on the discovery and validation of novel ta...

1 year ago - GlobeNewsWire

NexImmune Announces Melanoma Research Collaboration with NYU Langone's Perlmutter Cancer Center

GAITHERSBURG, MD, March 14, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targe...

1 year ago - GlobeNewsWire